Frovatriptan: Vernalis

Current Opinion in Investigational Drugs

Volumn 3, Issue 9, 2002, Pages 1373-1380

  Mucke, Hermann A M ^a  

^a HM Pharma Consultancy   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; DRUG METABOLITE; ERGOTAMINE TARTRATE; FROVATRIPTAN; FROVELAN; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; N ACETYLNORFROVATRIPTAN; NARATRIPTAN; PLACEBO; PROPRANOLOL; RIZATRIPTAN; SB 205555A; SB 210199; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEATH; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; GENOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MIGRAINE; NONHUMAN; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; THORAX PAIN; VASCULAR RESISTANCE; VASOCONSTRICTION;

CARBAZOLES; CLINICAL TRIALS; DRUG INDUSTRY; MIGRAINE DISORDERS; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0036771078     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. 102124 Cortical and striatal variations in drug combination studies with putative 5-hydroxytryptamine 1D binding sites. Peroutka SJ Brain Res 1991 553 2 206-210
2. 178546 SmithKline Beecham and Vanguard Medica collaborate on antimigraine drug. Vanguard Medica Press Release 1994 November 30
3. 188478 Research and Development Review - SB Pharmaceuticals: Development protfolio by Therapeutic Area. SmithKline Beecham Company Brochure 1995 October 02
4. 194382 Vanguard Medica initiates phase II clinical studies on anti-migraine drug. Vanguard Medical Press Release 1996 January 03
5. 1D receptors. Brown AM, Parsons AA, Raval P, Porter R, Tilford NS, Gager TL, Price GW, Wood MD, Kaumann AJ, Young RA, Rana K et al Br J Pharmacol 1996 119 Suppl 110P
6. 238129 A comparison of the agonist profile of SB 209509 (VML 251) and sumatriptan in human isolated basilar and coronary arteries. Raval P, Tilford NS, Porter R, Parsons AA, Smith SJ, King FD, Kaumann AJ, Hunter AJ Br J Pharmacol 1996 119 Suppl 111P
7. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME, Adham N, Zgombick JM, Cohen ML, Branchek TA, Phebus LA Neuroreport 1997 8 9-10 2237-2240
8. 1B/1D receptor agonist, SB 209509 (VML251), and sumatriptan in dogs. Parsons AA, Parker SG, Raval P, Campbell CA, Lewis VA, Griffiths R, Hunter AJ, Hamilton TC, King FD J Cardiovasc Pharmacol 1997 30 1 136-141
9. 287123 Vanguard Medica pursuing discussions with new commercial partner for frovatriptan. Vanguard Medica Press Release 1998 May 13
10. 300882 Elan licenses North American rights to Frovatriptan from Vanguard - Novel antimigraine therapy to be marketed by Elan Pharmaceuticals Division. Elan Corp Plc Press Release 1998 October 08
11. 1B/1D-receptor ligand frovatriptan in human isolated basilar and coronary arteries. Parsons AA, Raval P, Smith S, Tilford N, King FD, Kaumann AJ, Hunter J J Cardiovasc Pharmacol 1998 32 2 220-224
12. 303940 Comparison of the cardiovascular effects of SB 209509 (VML 251) and sumatriptan in dogs. Parsons AA, Parker SG, Raval P, Campbell CA, Hunter AJ, Hamilton TC, King FD Br J Pharmacol 1996 119 Suppl 109P
13. 319112 US clearance of Vanguard's deal with Elan triggers US$17.5 million in payments to Vanguagrd. Vanguard Medica Press Release 1998 November 26
14. 328515 Draxis acquires Canadian rights to eight neurology products from Elan - Elan takes quality stake in Draxis. Draxis Health Inc Press Release 1999 June 18
15. 1B/1D receptor agonists in migraine. Comparative pharmacology and its therapeutic implications. CNS Drugs 1998 10 4 271-286
16. 339335 Vanguard Medica Group Plc - Interim results for the six months ended 30 of June 1999. Vanguard Medica Group plc Press Release 1999 September
17. 342551 Acute management of migraine: Triptans and beyond. Diener HC, Limmroth V Curr Opin Neurol 1999 12 3 261-267
18. 352202 The triptans: A summary. CNS Drugs 1999 12 5 403-417
19. 352208 Effects of the novel antimigraine agent, frovatriptan, on coronary and cardiac function in dogs. Parsons AA, Valocik R, Koster P, Raval P, Gagnon R, Tilford N, Feuerstein G J Cardiovasc Pharmacol 1998 32 6 995-1000
20. 354794 Drug development pipeline: Frovatriptan. Draxis Pharma Inc Company Communication 2000 February 07
21. 355035 Drug development pipeline: Frovatriptan. Vanguard Medica Group Company Communication 2000 February 09
22. 7 receptors. Headache 1998 38 5 Poster 65
23. 1B/1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers. Buchan P Headache 1998 38 5 Poster 63
24. 355582 The effect of propranolol on the pharmacokinetic and safety profiles of frovatriptan. Buchan P, Ward C, Stewart AJ Headache 1999 39 5 345
25. 355583 Pharmacokinetics of frovatriptan in young and elderly subjects. Buchan P, Keywood C, Ward C, Oliver SD Headache 1999 39 5 346
26. 1D receptors. McHarg AD, Napier CM, Stewart M, Melrose HL, Wallis RM Headache 1999 39 5 369-370
27. 355585 Frovatriptan - Dose response studies. Rapoport AM, Keywood C Headache 1999 39 5 375
28. 375965 French Regulatory approval advised for Migard (frovatriptan). Vernalis Group Plc Press Release 2000 July 24
29. 377863 CPT 2000 (Part IX), Seventh Conference on Clinical Pharmacology and Therapeutics and Fourth Congress of the European Association for Clinical Pharmacology and Therapeutics, Florence, Italy. Archibald K IDDB Meeting Report 2000 July 15-20
30. 393608 Vernalis announces expansion of frovatriptan collaboration and new investment by Elan. Vernalis Group Plc Press Release 2000 December 13
31. 393612 Vernalis to buy out SmithKline Beecham royalties on frovatriptan. Vernalis Group Plc Press Release 2000 December 13
32. 399476 Healthcare - Elan. Morgan Stanley Dean Witter 2000 November 09
33. 413179 Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs. Carel I, Ghaleh B, Edouard A, Dubois-Rande JL, Parsons AA, Giudicelli JF, Berdeaux A Br J Pharmacol 2001 132 5 1071-1083
34. 422373 Specialty Pharmaceuticals - Brand-focused companies second quarter round-up. Salomon Smith Barney 2001 September 05
35. 422425 Elan Corp: Delivering. ABN Amro Bank NV USA 2001 April 05
36. 424603 Healthy mid-caps, Pan-European opportunities. Blum H Deutsche Banc Alex Brown 2001 September 25
37. 428943 FDA approves Elan's migraine drug Frova (frovatriptan succinate). Elan Corp Plc Press Release 2001 November 09
38. 437436 Vernalis announces successful conclusion of mutual recognition process for Frovatriptan. Vernalis Group Plc Press Release 2002 January 24
39. 438407 Elan reports 2001 financial results - Elan product revenue increases to $1.4 billion in 2001 - Elan reports earnings per share for the fourth quarter of 2001 of 56 cents (before other charges) - Elan provides earnings guidance for 2002. Elan Corp Plc Press Release 2002 February 04
40. 443769 Frovatriptan. Easthope SE, Goa KL CNS Drugs 2001 15 12 969-976
41. 443843 Clinical Review of Application No. 21-006 (frovatriptan, Miguard). United States Food and Drug Administration - Division of Neuropharmacological Drug Products 1999
42. 443848 Pharmacology Review of Application No. 21-006 (frovatriptan, Miguard). Atrakchi A Carcinogenicity Assessment Committee Report and FDA/CDER Rodent Carcinogenicity Database Factsheet 2001 October 02
43. 443851 Pharmacology Reviews of Application No. 21-006 (frovatriptan, Miguard), sponsor statements. Stolzenberg S United States Food and Drug Administration - Center of Drug Evaluation and Research
44. 444068 Vernalis records profit in second hald 2001 following Frova milestone payments. Vernalis Group Plc Press Release 2002 March 19
45. 444478 European biotech in focus (issue 1). Hermann M, Bennett S, Parkes R, Nagel R, Breijne J, Rivela J, Jost G 2002 March 04
46. 444493 Global Biotechnology quarterly - A political scorecard for Biotechnology in 2002. Schmidt E, Tanner W, Mehrotra R, Nadean P, Werber Y, Sinclair A, Vogel M SG Cowen Securities Corporation March 1
47. 444617 Drug development pipeline: Frovatriptan. Vernalis Research Ltd Company Communication 2002 March 22
48. 445135 Elan and UCB announce agreement to co-promote new migraine drug FROVA. Elan Corp Plc Press Release 2002 March 28
49. 445136 Vernalis welcomes appointment of US co-promotion partner for Frova. Vernalis Group Plc Press Release 2002 March 28
50. 450266 Elan reports first quarter 2002 financial results. Elan Corp Plc Press Release 2002 May 02
51. 455225 New option now available to treat migraine suffers. Elan Corp Plc Press Release 2002 June 19